Story thread · 3 reports / 3 sources
Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)
thestar.com · 3h · first report
DEGEVMA™ is now FDA-approved across all indications of the reference product, Xgeva® (denosumab), to help prevent bone complications in adults with advanced cancer that has spread to the bone, for the treatment of adults and skeletally mature adolescents with giant…
The coverage
- Teva wins biosimilar approval of Amgen's Xgeva
seekingalpha.com · 2h
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.